

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/165378 A2

(51) International Patent Classification:
Not classified

KNUTSSON, Ulrika; Cytiva Sweden AB, Björkgatan 30,
751 84 Uppsala (SE).

(21) International Application Number:
PCT/EP2024/052206

(74) Agent: **DÉMOULIN, Lotta** et al.; Cytiva Sweden AB,
Björkgatan 30, 751 84 Uppsala (SE).

(22) International Filing Date:
30 January 2024 (30.01.2024)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2350112-5 06 February 2023 (06.02.2023) SE

(71) Applicant: **CYTIVA BIOPROCESS R&D AB** [SE/SE];
Björkgatan 30, 751 84 Uppsala (SE).

(72) Inventors: **BJORKMAN, Tomas**; Cytiva Sweden AB,
Björkgatan 30, 751 84 Uppsala (SE). **RODRIGO, Gustav**;
Cytiva Sweden AB, Björkgatan 30, 751 84 Uppsala (SE).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: OPTIMIZATION OF ELUTION CONDITIONS




Fig. 2

(57) Abstract: The present invention relates to a method of purifying an antibody or an antibody fragment, adsorbing at least one of the antibody or the antibody fragment onto an affinity separation matrix by contacting a liquid sample with the affinity separation matrix; wherein the affinity matrix is an affinity separation matrix comprises a ligand based on Protein L, or any variation thereof that binds to a κ -light chain of the antibody or antibody fragment, and separating the at least one antibody or antibody fragment from the affinity separation matrix by using an elution buffer, wherein the elution buffer has concentration of 5-50 mM. It equally relates to a method for separation of bispecific antibodies.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*